UNSPSC 51201823: Molgramostim

This classification denotes a therapeutic granulocyte-macrophage colony-stimulating factor with the molecular formula C639H1007N171O196S8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B321AL142J, more generally known as molgramostim. European Medicines Agency schedules molgramostim in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09040MIG. The term MOLGRAMOSTIM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, no. 3 1991, list 31.

UNSPSC 51201823 Molgramostim is a Commodity code for a specific pharmaceutical product, but recent state and local procurement activity under this code shows no solicitations for molgramostim itself. The Mississippi State Department of Health posted a sole source notice on July 13, 2026, tagged to this code, but the actual procurement is for Yellow Fever Vaccine from Sanofi Pasteur, Inc.—a distinct pharmaceutical product unrelated to molgramostim's nominal scope. The mismatch suggests either a data-entry error in the code assignment or divergence between the taxonomy label and the agency's internal categorization. State and local health departments and purchasing offices would be the primary issuing bodies for pharmaceutical procurement under this code tier, but the single recent opportunity does not represent molgramostim activity.

The geographic activity captured here is limited to Mississippi. The sole source notice filed by the Mississippi State Department of Health, with objections due August 3, 2026, at 10:00 a.m. CST, is the only recent opportunity in the source. The notice invites any vendor to challenge the sole source classification by demonstrating that alternative suppliers can provide the vaccine; if substantiated objections are received, the department will conduct a competitive bid or selection process. No quantity, contract term, estimated value, or pricing information was disclosed in the notice. Given the absence of relevant molgramostim solicitations and the mismatch between the code assignment and the Yellow Fever Vaccine procurement, this code shows little actionable activity for vendors pursuing pharmaceutical contracts at the state or local level.